KR20100130020A - A composition comprising novel black ginseng without tumor promoting agents such as benzopyran and the extract thereof obtained by novel process - Google Patents
A composition comprising novel black ginseng without tumor promoting agents such as benzopyran and the extract thereof obtained by novel process Download PDFInfo
- Publication number
- KR20100130020A KR20100130020A KR1020090048666A KR20090048666A KR20100130020A KR 20100130020 A KR20100130020 A KR 20100130020A KR 1020090048666 A KR1020090048666 A KR 1020090048666A KR 20090048666 A KR20090048666 A KR 20090048666A KR 20100130020 A KR20100130020 A KR 20100130020A
- Authority
- KR
- South Korea
- Prior art keywords
- ginseng
- black ginseng
- hours
- extract
- black
- Prior art date
Links
- 241000208340 Araliaceae Species 0.000 title claims abstract description 114
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 114
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 114
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 114
- 238000000034 method Methods 0.000 title claims abstract description 26
- 239000000284 extract Substances 0.000 title claims description 20
- 230000008569 process Effects 0.000 title claims description 7
- 239000000203 mixture Substances 0.000 title description 33
- KYNSBQPICQTCGU-UHFFFAOYSA-N Benzopyrane Chemical compound C1=CC=C2C=CCOC2=C1 KYNSBQPICQTCGU-UHFFFAOYSA-N 0.000 title description 10
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000001737 promoting effect Effects 0.000 title 1
- 238000001035 drying Methods 0.000 claims abstract description 17
- 238000010025 steaming Methods 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 238000004519 manufacturing process Methods 0.000 claims description 25
- 229930182490 saponin Natural products 0.000 claims description 22
- 235000017709 saponins Nutrition 0.000 claims description 22
- 150000007949 saponins Chemical class 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 6
- -1 Rg 3 Chemical class 0.000 claims description 5
- 230000000711 cancerogenic effect Effects 0.000 claims description 4
- 231100000315 carcinogenic Toxicity 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 235000013376 functional food Nutrition 0.000 claims description 3
- 150000001562 benzopyrans Chemical class 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims 1
- 238000005406 washing Methods 0.000 claims 1
- 235000002789 Panax ginseng Nutrition 0.000 abstract description 20
- 235000013402 health food Nutrition 0.000 abstract description 4
- 240000004371 Panax ginseng Species 0.000 abstract 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 30
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 11
- 235000013361 beverage Nutrition 0.000 description 8
- 230000000052 comparative effect Effects 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000020710 ginseng extract Nutrition 0.000 description 8
- 244000309464 bull Species 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 239000003183 carcinogenic agent Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 230000009172 bursting Effects 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 230000002180 anti-stress Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000002443 hepatoprotective effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 238000003672 processing method Methods 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 235000013616 tea Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- FMMWHPNWAFZXNH-UHFFFAOYSA-N Benz[a]pyrene Chemical compound C1=C2C3=CC=CC=C3C=C(C=C3)C2=C2C3=CC=CC2=C1 FMMWHPNWAFZXNH-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000000049 anti-anxiety effect Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 238000003763 carbonization Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 210000002375 erythropoietic cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229940029988 ginseng preparation Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002883 vasorelaxation effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/03—Products from fruits or vegetables; Preparation or treatment thereof consisting of whole pieces or fragments without mashing the original pieces
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
- A23L2/04—Extraction of juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/40—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by drying or kilning; Subsequent reconstitution
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/10—Drying, dehydrating
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
Landscapes
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 인삼으로부터 적정 온도 및 시간으로 건조 및 증숙을 반복하는 공정을 통한 기존의 흑삼 제조방법에 비하여 시간이 단축되며, 대량생산이 가능한 고온·고압을 이용하여 Rg3, Rk1, Rg5, Rh1, Rh2 등과 같은 백삼이나 홍삼에 존재하지 않거나 미량 존재하는 사포닌들을 다량 함유하고, 벤조피란과 같은 발암성물질이 거의 검출되지 않는 우수한 품질의 흑삼의 신규 제조방법에 관한 것이다.The present invention is shortened compared to the conventional method for manufacturing black ginseng through the process of repeating drying and steaming at the appropriate temperature and time from ginseng, using high temperature and high pressure capable of mass production Rg 3 , Rk 1 , Rg 5 , The present invention relates to a novel method for producing black ginseng of good quality, containing a large amount of saponins that are not present in trace amounts or trace amounts of red ginseng or red ginseng such as Rh 1 , Rh 2, and the like, and hardly detectable carcinogenic substances such as benzopyran.
[문헌 1] Okamura N. et al., Biol. Pharm. Bull., 17(2), p.270, 1994Reference 1 Okamura N. et al., Biol. Pharm. Bull. , 17 (2) , p.270, 1994
[문헌 2] 대한민국 특허등록 제10-0543862호[Document 2] Republic of Korea Patent Registration No. 10-0543862
[문헌 3] Cha HY et al., Biol Pharm Bull., 28(9), pp.1621-1625, 2006Cha HY et al., Biol Pharm Bull., 28 (9) , pp.1621-1625, 2006
[문헌 4] Kang JS et al., Arch Pharm Res ., 28(3), pp.335-342, 2005Document 4 Kang JS et al., Arch Pharm Res . , 28 (3) , pp.335-342, 2005
[문헌 5] Kordella T et al., Diabetes Forecast , 57(1), pp.RG5-8, 2004[Reference 5] Kordella T et al., Diabetes Forecast , 57 (1) , pp.RG5-8, 2004
[문헌 6] Neuberger J et al., The Royal College of Physicians of London and the British Society of Gastroenterology ., 49, Suppl 1, pp.I1-21, 2001[6] Neuberger J et al., The Royal College of Physicians of London and the British Society of Gastroenterology ., 49 , Suppl 1, pp. I1-21, 2001
[문헌 7] Chung BC et al., Pharmacol Res ., 54(1), pp.46-49, 2006[Reference 7] Chung BC et al., Pharmacol Res . , 54 (1) , pp.46-49, 2006
[문헌 8] Huang C. et al., Sichuan Da Xue Xue Bao Yi Xue Ban , 37(1), pp.60-62, 2006[Reference 8] Huang C. et al., Sichuan Da Xue Xue Bao Yi Xue Ban , 37 (1) , pp. 60-62, 2006
[문헌 9] Kim DH et al., Biol Pharm Bull ., 28(10), pp.1992-1994, 2005Document 9 Kim DH et al., Biol Pharm Bull ., 28 (10) , pp. 1992-1994, 2005
[문헌 10] Sun YX et al., J Agric Food Chem ., 51(9), pp.2555-2558, 2003[Reference 10] Sun YX et al., J Agric Food Chem ., 51 (9) , pp. 2555-2558, 2003
[문헌 11] Qui H et al., Zhonghua Wai Ke Za Zhi , 40(8), pp.606-608, 2002[11] Qui H et al., Zhonghua Wai Ke Za Zhi , 40 (8 ), pp. 606-608, 2002
[문헌 12] Schini-Kerth VB et al., Eur J Pharmacol ., 367(1), pp.51-57, 199912 Schini-Kerth VB et al., Eur J Pharmacol . , 367 (1) , pp. 51-57, 1999
[문헌 13] Lee HK et al., Biol Pharm Bull ., 21(1), pp.79-80, 1998[Reference 13] Lee HK et al., Biol Pharm Bull ., 21 (1) , pp. 79-80, 1998
우리나라의 홍삼은 약 1,000년 전부터 제조된 역사적 기록을 가지고 있으며(중국 송나라의 서긍이 저술한 고려도경에 홍삼에 대한 기록이 있음), 한의학적 전통제약기술인 수치법에 의해 가공 제조된 수치생약이라 할 수 있다. 일반적으로 생약의 수치목적은 1) 독성 등 부작용의 경감, 2) 생약 성능의 개변과 약효의 증강, 3) 보관이나 저장성의 향상, 4) 맛과 냄새 교정 및 부색 등으로 알려지고 있다. 일반적으로 홍삼은 적정한 열처리 공정을 거치는 동안 2차적 성분변환이 일어나 수삼(fresh ginseng)이나 백삼에 존재하지 않는 홍삼 특유의 새로운 약효성분들이 생성되기도 하고, 어떤 활성성분은 함량 증가가 일어난다. 이렇듯 인삼의 가공방법에 따라 인삼에 존재하지 않는 새로운 성분이 생성되며 인삼에 비해서 항암작용을 비롯한 여러 가지 생리활성에 대해서 보다 우수한 효과를 나타내는 새로운 가공 인삼을 개발할 수 있다(Okamura N. et al., Biol . Pharm . Bull ., 17(2), p.270, 1994). Korean red ginseng has a historical record of about 1,000 years ago (there is a record of red ginseng in Goryeo-do, written by the Chinese Song Dynasty), and it is a numerical medicine processed and manufactured by numerical method, which is a traditional Chinese medicine. have. In general, the numerical objectives of herbal medicines are known as: 1) reducing side effects such as toxicity, 2) altering herbal properties and enhancing drug efficacy, 3) improving storage and storage, and 4) correcting taste and odor and color. In general, red ginseng undergoes a second ingredient conversion during an appropriate heat treatment process, thereby generating new active ingredients unique to red ginseng or fresh ginseng, and some active ingredients increase in content. As such, new ginsengs that do not exist in ginseng are produced according to the processing method of ginseng, and new processed ginseng can be developed that shows better effects on various physiological activities including anticancer activity than ginseng (Okamura N. et al., Biol . Pharm . Bull . , 17 (2) , p. 270, 1994).
중국의 경우, 백삼에는 거의 존재하지 않으며 홍삼에 소량 존재하는 인삼 사포닌인 Rg3를 대량 생산하는 방법을 개발하여 ‘Shenyi' 라는 상품명으로 항암치료를 위해 사용하고 있다. In China, it has developed a method of mass-producing Rg 3 , a ginseng saponin, which is rarely present in white ginseng and is present in small amounts in red ginseng, and is used for anticancer treatment under the trade name 'Shenyi'.
또한, 35억 달러 세계 인삼시장을 잡기 위하여 국내 바이오 벤처기업들이 인삼 관련 신 물질 개발에 열을 올리고 있다. 지금까지 인삼을 기능성식품으로 표준 화하여 세계 시장에서 성과를 올리고 있는 기업은 스위스 베링거잉겔하임 산하의 “파머톤사" 뿐이며, 국내에서도 인삼에 대한 국가차원의 연구와 벤처업계의 상품화가 속속 진행되고 있다. In addition, domestic bio venture companies are working hard to develop new ginseng-related materials to capture the $ 3.5 billion global ginseng market. Until now, the only company that has made ginseng standardized as a functional food and has been performing in the global market is the “Pharmton Company” under Beringer Ingelheim, Switzerland. National research on ginseng and commercialization of venture industry are in progress. .
한국생명공학연구원과 바이오벤처기업 비티진이 공동 개발한 ‘황삼EX’, ㈜남일농장 인삼영농조합이 바이오벤처기업인 ㈜그린바이오와 손잡고 제품화한 ‘팽화홍삼’, 남양알로에에서 분사한 ㈜유니젠이 최근 미국 UPI사와 공동으로 개발한 `바이오맥스', (주)CJ의 ‘식스플러스’, (주)일동제약의 ‘황삼’ 과 같은 여러 종류의 가공인삼이 개발되고 있다. 'Hwangsam EX' co-developed by Korea Research Institute of Biotechnology and biotechnology venture Vitijin, Namjin Farm Ginseng Farming Co. Several types of processed ginseng are being developed, such as Biomax, which was developed jointly with UPI in the United States, Six Plus of CJ, and Yellow Ginseng of Ildong Pharmaceutical.
또한, 최근에는 증숙법의 하나인 한약재의 가공방법 중 물과 불을 함께 사용하는 것으로 가장 대표적인 방법인 구증구포(九蒸九曝)의 원리(대한민국 특허등록 제10-0543862호) 흑삼이 개발된 바 있다.In addition, recently, the principle of Gujeunggupo (Korean Patent Registration No. 10-0543862) black ginseng, which is the most representative method, is to use water and fire together in the processing method of Chinese herbal medicine, one of the steaming methods. There is a bar.
그러나 상기의 방법은 아홉 번을 찌고 건조하는 과정에서 탄화 등과 같은 문제점이 발생할 수 있다. 실제로 이러한 방법에서 제조된 흑삼에서 벤조피란 등과 같은 발암성물질이 검출되어 사회적으로 물의를 일으키고 있는 실정이다. 또한 수삼을 건조하지 않고 직접 고온고압의 조건하에서 흑삼을 제조하면 제조하는 과정에서 수삼이 터지게 되므로 우수한 품질의 흑삼을 제조할 수 없다.However, the above method may cause problems such as carbonization in the process of steaming and drying nine times. In fact, carcinogenic substances such as benzopyrans are detected in black ginseng prepared in such a method, causing social controversy. In addition, if the black ginseng is manufactured under the conditions of high temperature and high pressure without drying the ginseng, the fresh ginseng may burst during the manufacturing process, and thus, black ginseng of excellent quality cannot be prepared.
따라서 본 발명은 인삼을 이용하여 구증구포의 방법에 비하여 시간이 단축되며, 대량생산이 가능하고, 터지지 않을 뿐만 아니라 탄화되지 않으며, Rg3, Rk1, Rg5, Rh1, Rh2 등과 같은 사포닌을 다량 함유하는 우수한 품질의 흑삼을 제조하여 본 발명을 완성하였다.Therefore, the present invention is reduced in time compared to the method of agglutination vesicles using ginseng, mass production is possible, not bursting, not carbonized, saponins such as Rg 3 , Rk 1 , Rg 5 , Rh 1 , Rh 2 The present invention was completed by preparing a good quality black ginseng containing a large amount.
상기의 목적을 달성하기 위하여 본 발명은 인삼을 건조, 증숙, 가열 및 건조하는 공정을 통하여 시간이 단축되고, 대량 생산이 가능한 고온·고압을 이용한 흑삼의 신규한 제조방법을 제공한다.In order to achieve the above object, the present invention provides a novel method for producing black ginseng using high temperature and high pressure, which is shortened in time through a process of drying, steaming, heating and drying ginseng.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 흑삼은 하기와 같이 제조될 수 있다. Black ginseng of the present invention can be prepared as follows.
본 발명은 인삼을 초음파 세척기로 세척 후, 20 내지 60℃, 바람직하게는 45 내지 60℃의 온도에서 24 내지 96시간, 바람직하게는 30 내지 48시간 동안 건조하여 수분함량이 20 내지 55%, 바람직하게는 25 내지 35%가 되도록 하는 1차 건조공정; 0.06 내지 0.50MPa, 바람직하게는 0.10 내지 0.25MPa의 압력 하에 105 내지 155℃, 바람직하게는 110 내지 135℃의 온도에서 1 내지 4시간, 바람직하게는 2 내지 3시간 동안 증숙하는 증숙공정; 40 내지 70℃, 바람직하게는 50 내지 60℃의 온도에서 24 내지 48시간, 바람직하게는 30 내지 40시간 동안 수분함량 14% 이내로 건조하는 2차 건조공정을 포함하는 흑삼의 신규한 제조방법을 제공한다.According to the present invention, the ginseng is washed with an ultrasonic cleaner and dried at a temperature of 20 to 60 ° C., preferably 45 to 60 ° C., for 24 to 96 hours, preferably 30 to 48 hours, so that the moisture content is 20 to 55%. Preferably a primary drying step of 25 to 35%; Steaming process for 1 to 4 hours, preferably 2 to 3 hours at a temperature of 105 to 155 ° C, preferably 110 to 135 ° C under a pressure of 0.06 to 0.50 MPa, preferably 0.10 to 0.25 MPa; It provides a novel manufacturing method of black ginseng comprising a secondary drying step of drying within 14% water content for 24 to 48 hours, preferably 30 to 40 hours at a temperature of 40 to 70 ℃, preferably 50 to 60 ℃ do.
상기 제조 방법에 의해 제조된 흑삼은 음건, 냉동건조 등의 당업계에 통상적인 건조방법을 통하여 건조한 후, 미세입자, 바람직하게는 약 50㎛ 내지 200㎛의 입자크기로 분쇄, 분말화하는 공정을 통하여 당업계에 잘 알려진 부형제 또는 담체를 이용하여 환제, 캅셀제, 정제 등의 조성물로 제조할 수 있다.The black ginseng prepared by the manufacturing method is dried through a drying method common in the art such as shade drying or freeze drying, and then pulverized and powdered into fine particles, preferably a particle size of about 50 μm to 200 μm. Through the use of excipients or carriers well known in the art can be prepared in compositions such as pills, capsules, tablets.
상기 방법에 의해 제조된 흑삼은 생약 분쇄기를 이용하여 미세분말, 바람직하게는 약 50 내지 200㎛ 크기의 분말로 분쇄하여 각종제제의 원료로 사용할 수 있다.The black ginseng prepared by the above method may be used as a raw material for various preparations by pulverizing into fine powder, preferably about 50 to 200 μm in size, using a herbal medicine grinder.
또한, 흑삼 추출물을 수득하는 방법을 자세히 설명하면, 상기 제조방법으로 제조한 흑삼을 분쇄한 후, 흑삼의 약 3 내지 7배, 바람직하게는 4 내지 6배(v/w)의 물을 가하여, 실온에서 3 내지 7시간 방치한 후, 물, 탄소수 1 내지 4의 저급알코올 또는 이들의 혼합용매로부터 선택된 용매를 0.5 내지 2ℓ를 가하여, 3시간 씩 3회 환류 추출한 다음, 실온까지 냉각시킨 후 여과한 뒤 감압농축기를 이용하여 에탄올을 제거하는 제조방법으로 본 발명의 흑삼 추출물을 수득할 수 있다. In addition, the method for obtaining black ginseng extract in detail, after pulverizing the black ginseng prepared by the above production method, by adding about 3 to 7 times, preferably 4 to 6 times (v / w) water of black ginseng, After standing at room temperature for 3 to 7 hours, 0.5-2 L of a solvent selected from water, a lower alcohol having 1 to 4 carbon atoms or a mixed solvent thereof was added thereto, and the mixture was extracted under reflux three times for 3 hours, and then cooled to room temperature and filtered. The black ginseng extract of the present invention may be obtained by a method of removing ethanol using a vacuum concentrator.
상기 제조방법에 의해 제조된 흑삼에는 홍삼에 미량 존재하는 Rg3, Rk1, Rg5, Rh1, Rh2 등과 같은 사포닌이 다량 존재하고 있다. 이 사포닌 성분 중 Rg5 는 항암 효과, 항당뇨 효과 등을, Rg3은 항스트레스 효과, 간보호 효과, 항산화 효과 등의 다양한 약리 활성을 나타내므로, 본 발명의 흑삼은 위와 같은 다양한 생리 활성을 나타낼 수 있다. 또한 제조한 흑삼 중에 존재하는 발암성물질인 벤조피란의 함량을 측정한 결과, 2ppb 이하로 검출됨을 확인할 수 있었다.The black ginseng prepared by the preparation method has a large amount of saponins such as Rg 3 , Rk 1 , Rg 5 , Rh 1 , and Rh 2 present in trace amounts in red ginseng. Among the saponin components, Rg 5 has various pharmacological activities such as anticancer effect, antidiabetic effect, and Rg 3 has anti-stress effect, hepatoprotective effect and antioxidant effect. Can be. In addition, as a result of measuring the content of benzopyran, a carcinogenic substance present in the prepared black ginseng, it was confirmed that it is detected at 2ppb or less.
본 발명의 제조방법은 인삼 자체뿐만 아니라 인삼잎에도 적용될 수 있다. 인삼잎은 지금까지 약용으로 사용하지는 않고 그냥 버리거나 사료용으로 사용되었으며, 일부가 향장품 또는 식품의 원료로 사용되어 왔을 뿐이나, 인삼잎 추출물을 본 발명에서와 같은 방법으로 가열, 가압처리 할 경우 약효가 훨씬 강화되므로 이제까 지의 인삼잎의 용도에는 물론이고 약용으로도 사용될 수 있다. The production method of the present invention can be applied to ginseng leaves as well as ginseng itself. Ginseng leaves have not been used for medicinal purposes, but have been discarded or used for feed, and some of them have been used as raw materials for cosmetics or foods.However, when ginseng leaf extract is heated and pressurized in the same way as in the present invention, Since it is much stronger, it can be used for medicinal purposes as well as for the use of ginseng leaves.
상기 방법으로 제조된 흑삼은 기존의 수삼이나 백삼, 또는 홍삼에는 없거나, 극미량으로 존재하던 활성 성분의 함량을 증강시킴을 특징으로 한다.The black ginseng prepared by the above method is characterized in that the existing ginseng, white ginseng, or red ginseng does not exist or enhances the content of the active ingredient present in trace amounts.
본 발명은 상기의 제조방법으로 제조하여 벤조피란과 같은 발암성물질이 거의 검출되지 않고 Rg3, Rk1, Rg5, Rh1, Rh2 등의 사포닌들을 다량 함유한 흑삼 또는 그 추출물을 유효성분으로 함유하는 건강기능식품을 제공한다. The present invention is prepared by the production method described above is rarely detected carcinogenic substances such as benzopyran and black ginseng or its extract containing a large amount of saponins, such as Rg 3 , Rk 1 , Rg 5 , Rh 1 , Rh 2 as an active ingredient Provides health functional foods containing.
본 발명의 제조방법으로 수득한 흑삼 또는 그 추출물을 포함하는 조성물은 약제, 식품 및 음료 등에 다양하게 이용될 수 있다. 본 발명의 흑삼 또는 그 추출물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강보조 식품류 등이 있고, 분말, 과립, 정제, 캡슐 또는 음료인 형태로 사용할 수 있다.The composition comprising the black ginseng obtained by the manufacturing method of the present invention or its extract may be used in a variety of drugs, food and beverages. The food to which the black ginseng or the extract of the present invention may be added includes, for example, various foods, beverages, gums, teas, vitamin complexes, health supplements, and the like, and are powders, granules, tablets, capsules, or beverages. Can be used as
이 때, 식품 또는 음료 중의 상기 흑삼 또는 그 추출물의 양은 일반적으로 전체 식품 중량의 0.01 내지 15 중량%로 가할 수 있으며, 건강 음료 조성물은 100 ㎖를 기준으로 0.02 내지 10 g, 바람직하게는 0.3 내지 1 g의 비율로 가할 수 있다. At this time, the amount of the black ginseng or its extract in the food or beverage may be generally added at 0.01 to 15% by weight of the total food weight, the health beverage composition is 0.02 to 10 g, preferably 0.3 to 1 based on 100 ml It can be added in the ratio of g.
본 발명의 건강 음료 조성물은 지시된 비율로 필수 성분으로서 상기 흑삼 또는 그 추출물을 함유하는 것 외에 액체성분에는 특별한 제한점은 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등 의 디사카라이드, 예를 들어 말토스, 슈크로스 등의 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제(타우마틴, 스테비아 추출물(예를 들어, 레바우디오시드 A, 글리시르히진 등) 및 합성 향미제(사카린, 아스파르탐 등)를 유리하게 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 mL당 일반적으로 약 1 내지 20g, 바람직하게는 약 5 내지 12g이다.In addition to containing the black ginseng or its extract as an essential ingredient in the indicated ratio, the health beverage composition of the present invention does not have any particular limitation on the liquid component and may contain various flavors or natural carbohydrates as additional ingredients, such as ordinary drinks. Can be. Examples of the above-mentioned natural carbohydrates are conventional monosaccharides such as disaccharides such as glucose and fructose, such as maltose, sucrose and the like, and polysaccharides such as dextrin, cyclodextrin and the like. Sugars and sugar alcohols such as xylitol, sorbitol, and erythritol. As flavoring agents other than those mentioned above, natural flavoring agents (tauumatin, stevia extract (e.g., Rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. The proportion of natural carbohydrates is generally about 1 to 20 g, preferably about 5 to 12 g per 100 mL of the composition of the present invention.
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그밖에 본 발명의 조성물들은 천연 과일 쥬스 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 조성물 100 중량부 당 0 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above-mentioned composition, the composition of the present invention can be used as a flavoring agent such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and intermediates (cheese, chocolate etc.), pectic acid and its salts, Salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages and the like. In addition, the compositions of the present invention may contain flesh for the production of natural fruit juices and vegetable beverages. These components can be used independently or in combination. The proportion of such additives is not so critical, but is generally selected in the range of 0 to about 20 parts by weight per 100 parts by weight of the composition of the present invention.
본 발명에 의해서 개발된 흑삼의 제조방법은 기존 구증구포의 방법에 비하여 획기적으로 시간이 단축되고, 대량 생산이 가능한 고온·고압을 이용한 것으로, 본 발명을 통하여 얻어진 일정한 온도, 압력 및 수분함량 조건하에 제조된 흑삼의 경 우, 제조공정 중에 발생하는 터짐과 같은 불량품이 거의 없으며, 홍삼에 미량으로 존재하는 Rg3, Rk1, Rg5, Rh1, Rh2 등이 다량 존재하여 결과적으로 우수한 품질의 획기적인 흑삼을 제공할 수 있다.The manufacturing method of the black ginseng developed by the present invention uses a high temperature and high pressure, which is significantly shorter in time and mass-produced, compared to the existing augmentation vesicles, under the conditions of constant temperature, pressure and water content obtained through the present invention. In the case of manufactured black ginseng, there are few defects such as bursts occurring during the manufacturing process, and a large amount of Rg 3 , Rk 1 , Rg 5 , Rh 1 , Rh 2, etc., present in trace amounts in red ginseng results in excellent quality. It can provide breakthrough black ginseng.
이하, 본 발명을 하기 실시예 및 실험예에 의해 상세히 설명한다.Hereinafter, the present invention will be described in detail with reference to the following examples and experimental examples.
단, 하기 실시예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예 및 실험예에 의해 한정되는 것은 아니다.However, the following Examples and Experimental Examples are merely illustrative of the present invention, and the content of the present invention is not limited by the following Examples and Experimental Examples.
비교실시예Comparative Example 1. One. 구증구포Gujeungpo 흑삼 추출물의 제조 Preparation of Black Ginseng Extract
금산에서 재배한 5년근 수삼 1kg을 구입하여(금산인삼조합), 초음파 세척기에 넣고 15분간 총 3회 반복해서 세척하였다. 세척된 수삼을 증숙기에 넣고 예열시간을 제외하고 95℃에서 6시간 1차 증숙하였다. 예열시간은 증숙기에서 수증기가 세어 나오는 데까지의 시간으로 통상 30여분 소요되었으며, 열선이 내장된 건조기의 내부온도를 60℃로 유지시킨 후 펜을 돌리면서 골고루 1차 증숙한 인삼을 12시간 동안 1차 건조시켰다.1kg of 5 year old ginseng grown in Geumsan was purchased (Gumsan Ginseng Combination), put into an ultrasonic cleaner and washed repeatedly three times for 15 minutes. The washed ginseng was put into a steamer and steamed for 1 hour at 95 ° C except for the preheating time. The preheating time is typically 30 minutes, which is the time from the steamer to the water vapor, and after maintaining the internal temperature of the dryer with built-in heating wire at 60 ℃, rotate the pen evenly for the first time. Tea was dried.
상기와 같은 증숙 및 건조과정을 9번 반복하여 백색의 인삼이 홍색을 거쳐 흑색으로 변한 수분함량이 14% 이하의 흑삼을 제조하였다. By repeating the steaming and drying process 9 times as described above, a black ginseng having a water content of 14% or less was changed to black through white ginseng.
상기에서 제조한 흑삼 10g을 취하여 다음과 같은 추출방법으로 3번 추출하여 HPLC에 주입하여 분석하였다. 즉, 흑삼 10g을 칭량하여 헥산 100 ㎖을 넣어 섞어 준 다음, 물:DMF 혼합액(1:9) 50 ㎖를 넣어 균일하게 흔들어 섞어준 다음 DMF와 헥산을 분리시켰다. 다시 헥산층에 DMF혼합액 25 ㎖을 넣어 추출하였다. 이 조작을 2회 반복하여 총 DMF가 100 ㎖가 되도록 하였다. 분리된 DMF 혼액층에 1% 황산나트륨 용액 100 ㎖을 넣고 충분히 섞은 후, 헥산 50 ㎖를 넣고 추출하고 다시 헥산 35 ㎖를 넣고 2회 더 추출하였다. 헥산 층을 증류수로 3회 세척하여 무수황산나트륨으로 탈수한 후 40 ℃에서 감압 농축하여 발암성 물질의 시료로 사용하였다(이하, GS라 명명함). 10 g of the black ginseng prepared above was taken, extracted three times by the following extraction method, and injected into HPLC for analysis. That is, 10 g of black ginseng was weighed and mixed with 100 ml of hexane. Then, 50 ml of water: DMF mixed solution (1: 9) was added and shaken uniformly to separate DMF and hexane. 25 ml of DMF mixture was added to the hexane layer and extracted. This operation was repeated twice to bring the total DMF to 100 ml. 100 ml of 1% sodium sulfate solution was added to the separated DMF mixed layer, and the mixture was sufficiently mixed. Then, 50 ml of hexane was added thereto, followed by extraction. The hexane layer was washed three times with distilled water, dehydrated with anhydrous sodium sulfate, and concentrated under reduced pressure at 40 ° C. to use as a sample of carcinogenic substance (hereinafter referred to as GS).
비교실시예Comparative Example 2. 수삼에서 직접 고온고압을 이용한 2. Using high temperature and high pressure directly in fresh ginseng 흑삼의 제조Preparation of Black Ginseng
금산에서 재배한 5년근 수삼 1kg을 구입하여(금산인삼조합), 초음파 세척기에 넣고 15분간 총 3회 반복해서 세척하였다. 세척된 수삼을 증숙기에 넣고 예열시간을 제외하고 가압하에(0.13MPa) 119℃에서 3시간 증숙하였다. 예열시간은 증숙기에서 수증기가 세어 나오는 데까지의 시간으로 통상 30여분 소요되었으며, 증숙과정 중에 수삼을 건조하지 않고 압력을 가했기 때문에 조직이 파괴되어 사포닌과 같은 유효성분이 조직밖으로 흘러나옴을 확인할 수 있었다. 열선이 내장된 건조기의 내부온도를 60℃로 유지시킨 후 펜을 돌리면서 골고루 1차 증숙한 인삼을 12시간 동안 1차 건조시켰다. 1kg of 5 year old ginseng grown in Geumsan was purchased (Gumsan Ginseng Combination), put into an ultrasonic cleaner and washed repeatedly three times for 15 minutes. The washed ginseng was put into a steamer and steamed for 3 hours at 119 ° C under pressure (0.13 MPa) except for the preheating time. The preheating time is usually 30 minutes from the steamer to the water vapor, and the tissue was destroyed because the ginseng was pressed without drying during steaming, and the active ingredient, such as saponin, flowed out of the tissue. . After maintaining the internal temperature of the dryer with a built-in heating wire at 60 ℃, the first ginseng evenly steamed while rotating the pen was first dried for 12 hours.
비교실시예Comparative Example 3. 홍삼 추출물의 제조 3. Preparation of Red Ginseng Extract
금산에서 재배한 5년근 수삼 1kg을 구입하여(금산인삼조합), 초음파 세척기에 넣고 15분간 총 3회 반복해서 세척하였다. 세척된 수삼을 증숙기에 넣고 예열시간을 제외하고 95℃에서 3시간 증숙하였다. 예열시간은 증숙기에서 수증기가 세어 나오는 데까지의 시간으로 통상 30여분 소요되었으며, 열선이 내장된 건조기의 내부온도를 55℃로 유지시킨 후 펜을 돌리면서 골고루 증숙한 인삼을 48시간 동안 건조시켜 홍삼 256g을 얻었다. 1kg of 5 year old ginseng grown in Geumsan was purchased (Gumsan Ginseng Combination), put into an ultrasonic cleaner and washed repeatedly three times for 15 minutes. The washed ginseng was put into a steamer and steamed for 3 hours at 95 ° C except for the preheating time. The preheating time is usually 30 minutes, which is the time from the steamer to the water vapor.The red ginseng is dried for 48 hours while keeping the internal temperature of the dryer with built-in wire at 55 ℃ and rotating the pen evenly. 256 g was obtained.
제조한 홍삼 50g을 분쇄한 후 80%에탄올 1L를 넣고 4시간씩 3회 환류 추출한 다음, 추출한 용액을 실온까지 냉각시킨 후 여과한 뒤, 감압 농축기로 용매를 제거하여 홍삼 조추출물 19g을 수득하였고, 이 홍삼 조추출물에 물 300㎖를 넣어 현탁시킨 후 에테르 300㎖를 가하여 비극성 물질을 제거하였으며, 남아있는 수층에 수포화 부탄올 300㎖를 가하여 인삼에 존재하는 사포닌을 추출한 후 부탄올을 감압농축기로 제거하여 인삼 사포닌이 다량 함유된 홍삼 추출물 4.8g을 얻었으며 이를 사포닌 함량을 측정하기 위한 시료로 사용하였다(이하, RGS라 명명함).50 g of the prepared red ginseng was pulverized, and 1L of 80% ethanol was added thereto, and the mixture was extracted at reflux three times for 4 hours. 300 ml of water was added to the red ginseng crude extract and suspended. Then, 300 ml of ether was added to remove the nonpolar substance. 4.8 g of red ginseng extract containing a large amount of ginseng saponin was obtained and used as a sample for measuring saponin content (hereinafter referred to as RGS).
실시예Example 1. 흑삼의 제조 1. Preparation of Black Ginseng
금산에서 재배한 5년근 인삼 1kg을 구입하여(금산인삼조합), 초음파 세척기 에 넣고 10분간 총 3회 반복해서 세척하였다. 세척된 인삼을 비교실시예 2와 같이 흑삼제조과정 중에 조직이 터지는 것을 방지하기 위하여 55℃에서 36시간 1차 건조하여 수분함량이 30%가 되도록 하였다. 1차 건조한 수분함량이 30%인 인삼을 다시 가압하에(0.13MPa) 119℃에서 3시간 증숙한 후, 건조기로 55℃에서 30시간 동안 2차 건조하여 수분함량이 14%인 본 발명의 흑삼 238g을 제조하였다. 1kg of 5-year-old ginseng grown in Geumsan was purchased (Gumsan Ginseng Combination), put into an ultrasonic cleaner, and washed repeatedly three times for 10 minutes. The washed ginseng was first dried at 55 ° C. for 36 hours to prevent tissue from bursting during the manufacturing process of black ginseng, as in Comparative Example 2, so that the moisture content was 30%. First, the ginseng with 30% moisture content is steamed again (0.13MPa) at 119 ° C for 3 hours, and then dried for 2 hours at 55 ° C with a dryer for 2 hours. Was prepared.
상기에서 제조한 흑삼 10g을 취하여 다음과 같은 추출방법으로 3번 추출하여 HPLC에 주입하여 분석하였다. 즉, 흑삼 10g을 칭량하여 헥산 100 ㎖을 넣어 섞어 준 다음, 물:DMF 혼합액(1:9) 50 ㎖를 넣어 균일하게 흔들어 섞어준 다음 DMF와 헥산을 분리시켰다. 다시 헥산층에 DMF혼합액 25 ㎖을 넣어 추출하였다. 이 조작을 2회 반복하여 총 DMF가 100 ㎖가 되도록 하였다. 분리된 DMF 혼액층에 1% 황산나트륨 용액 100 ㎖을 넣고 충분히 섞은 후, 헥산 50 ㎖를 넣고 추출하고 다시 헥산 35 ㎖를 넣고 2회 더 추출하였다. 헥산 층을 증류수로 3회 세척하여 무수황산나트륨으로 탈수한 후 40 ℃에서 감압 농축하여 발암성 물질의 시료로 사용하였다(이하, NGS라 명명함). 10 g of the black ginseng prepared above was taken, extracted three times by the following extraction method, and injected into HPLC for analysis. That is, 10 g of black ginseng was weighed and mixed with 100 ml of hexane. Then, 50 ml of water: DMF mixed solution (1: 9) was added and shaken uniformly to separate DMF and hexane. 25 ml of DMF mixture was added to the hexane layer and extracted. This operation was repeated twice to bring the total DMF to 100 ml. 100 ml of 1% sodium sulfate solution was added to the separated DMF mixed layer, and the mixture was sufficiently mixed. Then, 50 ml of hexane was added thereto, followed by extraction. The hexane layer was washed three times with distilled water, dehydrated with anhydrous sodium sulfate, and concentrated under reduced pressure at 40 ° C. to use as a sample of carcinogenic substance (hereinafter referred to as NGS).
실시예Example 2. 흑삼 추출물의 제조 2. Preparation of Black Ginseng Extract
상기의 실시예 1의 방법으로 제조된 흑삼 20g를 각각 취해 100㎖의 물을 넣고 실온에서 5시간 방치한 뒤 80% 에탄올(20% 물) 1ℓ를 가하여 3시간 씩 3회 환류 추출하여, 추출한 용액을 실온까지 냉각시킨 후 여과한 뒤 감압 농축기를 이용하여 에탄올을 제거하고 흑삼 추출물을 수득하였다(5.76g). 이 흑삼 추출물에 물 500㎖을 넣어 현탁시킨 후 에테르 500㎖을 가하여 비극성 물질을 제거하였다. 남아있는 수층에 수포화 부탄올 500㎖을 가하여 인삼에 존재하는 사포닌을 4회 추출한 후 부탄올을 감압농축기로 제거하여 인삼 사포닌이 다량 함유된 부탄올 추출물(조 사포닌 추출물)을 얻었다(1.98g). Take 20 g of black ginseng prepared by the method of Example 1, add 100 ml of water, and leave it at room temperature for 5 hours, extract 1 ml of 80% ethanol (20% water) and reflux 3 times for 3 hours to extract the extracted solution. After cooling to room temperature and filtered, ethanol was removed using a vacuum concentrator to obtain a black ginseng extract (5.76g). 500 ml of water was added to the black ginseng extract and suspended, and 500 ml of ether was added to remove the nonpolar material. 500 ml of saturated butanol was added to the remaining aqueous layer, followed by extraction of saponin present in ginseng four times, followed by removing butanol with a reduced pressure concentrator to obtain a butanol extract (crude saponin) containing a large amount of ginseng saponin (1.98 g).
이 흑삼 조 사포닌 추출물을 사포닌 성분 분석의 시료로 사용하였다(이하, NGSS 라 명명함).This black ginseng crude saponin extract was used as a sample for saponin component analysis (hereinafter referred to as NGSS).
실험예Experimental Example 1. 흑삼의 사포닌 함량분석 1. Saponin Content Analysis of Black Ginseng
상기 비교실시예 3에서 수득한 홍삼 추출물(RGS) 및 실시예 2에서 수득한 흑삼 조 사포닌 추출물(NGSS)의 사포닌 함량을 하기 표 1의 HPLC 분석 조건에서 하기와 같이 분석하여 그 결과를 하기 표 2에 나타내었다.The saponin content of the red ginseng extract (RGS) obtained in Comparative Example 3 and the black ginseng saponin extract (NGSS) obtained in Example 2 was analyzed in the HPLC analysis conditions of Table 1 below, and the results are shown in Table 2 below. Shown in
0분(0%B), 0-10분(30% B), 10-25분(50% B), 25-40분(100% B), 40-50분(100% B), 50-55분(0% B), 55-58분(0% B)A; CH 3 CN: H 2 O: 5% CH 3 COOH = 15: 80: 5, B; CH 3 CN: H 2 O = 80:20
0 minutes (0% B), 0-10 minutes (30% B), 10-25 minutes (50% B), 25-40 minutes (100% B), 40-50 minutes (100% B), 50- 55 minutes (0% B), 55-58 minutes (0% B)
실험결과, 표 2에 나타난 바와 같이, 홍삼에는 Rg3, Rh1, Rh2 및 Rk1 + Rg5가 각각 0.066%, 0.069%, 0.051% 및 0.075%로써 미량 존재하였지만, 본 발명에 의해서 제조된 흑삼에는 Rg3, Rh1, Rh2 및 Rk1 + Rg5가 각각 0.98%, 0.094%, 0.085% 및 1.19%로써 특히 Rg3와 Rk1 + Rg5가 15배 이상 존재함을 확인할 수 있었다.As a result, as shown in Table 2, red ginseng contained a small amount of Rg 3 , Rh 1 , Rh 2 and Rk 1 + Rg 5 as 0.066%, 0.069%, 0.051% and 0.075%, respectively. In black ginseng, Rg 3 , Rh 1 , Rh 2, and Rk 1 + Rg 5 were 0.98%, 0.094%, 0.085%, and 1.19%, respectively, and Rg 3 and Rk 1 + Rg 5 were 15 times more present.
실험예 2. 흑삼 중에 존재하는 발암성물질인 벤조피란 함량분석Experimental Example 2. Analysis of benzopyran content, a carcinogenic substance present in black ginseng
2-1. 분석기기 조건2-1. Analyzer condition
사용한 HPLC는 Waters alliance system을 사용 하였고, 여기 파장 294nm, 형광 파장 404nm, 컬럼 온도는 30℃, 이동상으로는 아세토니트릴 : 3차 증류수(80:20), 유속은 1.0 ㎖/min에서 정량하였다.HPLC was used for the Waters alliance system, excitation wavelength 294nm, fluorescence wavelength 404nm, column temperature was 30 ℃, acetonitrile: tertiary distilled water (80:20) as a mobile phase, the flow rate was quantified at 1.0 mL / min.
2-2. 직선성, 검출한계(LOD) 및 정량한계(LOQ)2-2. Linearity, Detection Limit (LOD) and Quantitative Limit (LOQ)
벤조피렌 표준품 50㎎을 정밀히 측정하여 메탄올에 녹여 정확히 50 ㎖로 하여 표준원액으로 한 다음, 이를 희석하여 7.8125, 15.625, 31.25, 62.5 및 125 ng/㎖의 농도별 표준액을 제조하여 분석 조건에 의한 피크 면적을 구하여 검량선을 작성하였다. 작성된 검량선으로부터 직선식의 상관계수 (기준: R2=0.99 이상)를 구하여 직선성을 검토 하였고, 3번 반복 실험하여 평가하였다.50 mg of benzopyrene standard is precisely measured, dissolved in methanol to make exactly 50 ml, and then diluted to prepare a standard stock solution. Diluted to prepare a standard solution for each concentration of 7.8125, 15.625, 31.25, 62.5 and 125 ng / ml, and the peak area according to the analysis conditions. The calibration curve was prepared by obtaining. From the calibration curve, the linear correlation coefficient (standard: R 2 = 0.99 or more) was obtained, and the linearity was examined.
검량선의 직선성 범위가 좋은 부분을 이용하여 하기의 수학식 1 및 수학식 2를 이용하여 검출한계 (LOD) 및 정량한계 (LOQ)를 산출하였다.The detection limit (LOD) and the quantitative limit (LOQ) were calculated using the following equations (1) and (2) by using a portion having a good linearity range of the calibration curve.
(σ는 절편의 평균표준편차이며, s는 기울기의 평균을 의미한다.)(σ is the mean standard deviation of the intercepts, and s is the mean of the slopes.)
흑삼 추출물에 존재하는 발암성 물질인 벤조피란의 함량을 분석한 결과, 표 3에 나타난바와 같이, 비교실시예 1에서 구증구포의 방법을 이용하여 제조한 흑삼(GS)에는 기준치인 2ppb를 초과하여 벤조피란이 검출되었다. 이에 비하여 실시예 1에서 고온,고압의 방법을 이용하여 제조한 흑삼(NGS)에는 0.32ppb로 기준치 이하로 벤조피란이 검출됨을 확인할 수 있었다. As a result of analyzing the content of benzopyran, a carcinogenic substance present in the black ginseng extract, as shown in Table 3, the black ginseng (GS) prepared by the method of erythropoietic cell in Comparative Example 1 exceeded 2 ppb as a reference value. Benzopyran was detected. On the other hand, black ginseng (NGS) prepared by using the method of high temperature and high pressure in Example 1, it was confirmed that benzopyran is detected below the reference value of 0.32ppb.
상기의 결과로부터 본 발명의 방법으로 제조된 흑삼(NGS)은 제조공정 중에 터지지 않고 인삼 원형그대로의 모습을 유지하였을 뿐만 아니라, 최근에 논란이 되고 있는 벤조피란과 같은 발암성물질이 거의 검출되지 않아 우수한 품질의 흑삼을 제조할 수 있음을 확인할 수 있었다. From the above results, the black ginseng (NGS) prepared by the method of the present invention not only kept the original shape of ginseng without bursting during the manufacturing process, and almost no carcinogenic substance such as benzopyran, which was recently controversial, was not detected. It was confirmed that black ginseng of good quality could be prepared.
한편, 증숙에 의해서 특이적으로 많이 생성되는 Rg5는 항불안효과(Cha HY et al., Biol Pharm Bull., 28(9), pp.1621-1625, 2006), 뇌기능개선효과(Kang JS et al., Arch Pharm Res., 28(3), pp.335-342, 2005),항당뇨효과(Kordella T et al., Diabetes Forecast, 57(1), pp.RG5-8, 2004) 및 C형 간염억제효과(Neuberger J et al., The Royal College of Physicians of London and the British Society of Gastroenterology., 49, Suppl 1, pp.I1-21, 2001) 등, Rg3는 항스트레스효과(Chung BC et al., Pharmacol Res., 54(1), pp.46-49, 2006), 항암효과(Huang C. et al., Sichuan Da Xue Xue Bao Yi Xue Ban, 37(1), pp.60-62, 2006), 간보호효과(Kim DH et al., Biol Pharm Bull., 28(10), pp.1992-1994, 2005), 항산화효과(Sun YX et al., J Agric Food Chem., 51(9), pp.2555-2558, 2003), 신생혈관억제효과(Qui H et al., Zhonghua Wai Ke Za Zhi, 40(8), pp.606-608, 2002), 혈관이완작용(Schini-Kerth VB et al., Eur J Pharmacol., 367(1), pp.51-57, 1999) 및 혈소판응집억제작용(Lee HK et al., Biol Pharm Bull., 21(1), pp.79-80, 1998) 등과 같은 여러 가지 생리활성을 나타낸다고 알려져 있어 이러한 사포닌이 다량 함유하는 흑삼은 위와 같은 다양한 생리활성을 기대할 수 있다.On the other hand, Rg 5, which is produced specifically by steaming, has an anti-anxiety effect (Cha HY et al., Biol Pharm Bull., 28 (9) , pp.1621-1625, 2006), brain function improvement effect (Kang JS et al., Arch Pharm Res. , 28 (3) , pp.335-342, 2005), antidiabetic effects (Kordella T et al., Diabetes Forecast, 57 (1) , pp.RG5-8, 2004) and hepatitis C inhibitory effects (Neuberger J et al., the Royal College of Physicians of London and the British Society of Gastroenterology., 49, Suppl 1, pp.I1-21, 2001) , etc., Rg 3 is anti-stress effect (Chung BC et al., Pharmacol Res. , 54 (1) , pp.46-49, 2006), anticancer effect (Huang C. et al., Sichuan Da Xue Xue Bao Yi Xue Ban, 37 (1) , pp. 60 -62, 2006), hepatoprotective effect (Kim DH et al., Biol Pharm Bull., 28 (10) , pp. 1992-1994, 2005), antioxidant effect (Sun YX et al., J Agric Food Chem., 51 (9) , pp.2555-2558, 2003), angiogenesis inhibitory effect (Qui H et al., Zhonghua Wai Ke Za Zhi, 40 (8 ), pp.606-608, 2002), vasorelaxant effect (Schini -Kerth VB et al., Eur J Pharmacol., 367 (1), pp.51-57, 1999) Platelet aggregation inhibitory action (Lee HK et al., Biol Pharm Bull., 21 (1), pp.79-80, 1998) it is known to exhibit various physiological activities that heuksam this saponin-containing large amounts, such as the above, a variety of Biological activity can be expected.
실험예 3. 급성독성실험Experimental Example 3. Acute Toxicity Test
6 주령의 특정병원체부재(specific pathogen-free, SPF) SD계 랫트를 사용하여 급성독성실험을 실시하였다. 각 그룹 당 2마리씩의 동물에 상기 실시예 2의 흑삼 추출물을 1g/㎏의 용량으로 1회 경구투여 하였다. 실험 물질 투여 후 동물의 폐사여부, 임상증상 및 체중변화를 관찰하고 혈액학적 검사와 혈액생화학적 검사를 실시하였으며, 부검하여 육안으로 강장기와 흉강 장기의 이상여부를 관찰하였다.Acute toxicity test was performed using 6-week-old specific pathogen-free (SPF) SD rats. Two animals of each group were orally administered to the black ginseng extract of Example 2 at a dose of 1 g / kg. After administration of the test substance, mortality, clinical symptoms, and changes in body weight were observed. Hematological and hematological examinations were performed. Necropsy was performed to visually observe abnormalities in organs and thoracic organs.
그 결과, 실험 물질을 투여한 모든 동물에서 특이할 만한 임상증상이나 폐사된 동물은 없었으며, 체중변화, 혈액검사, 혈액생화학 검사 및 부검 소견 등에서도 독성변화는 관찰되지 않았다. As a result, no clinical symptoms or dead animals were observed in all animals treated with the test substance, and no toxic changes were observed in weight changes, blood tests, blood biochemical tests, and autopsy findings.
따라서 본 발명의 추출물은 랫트에서 각각 1g/㎏까지도 독성변화를 나타내지 않으므로 경구투여 최소치사량(LD50)은 1g/㎏이상인 안전한 물질로 판단되었다. Therefore, the extract of the present invention does not show a toxic change in each rat up to 1 g / kg, oral administration minimum dose (LD 50 ) was determined to be a safe substance of more than 1 g / kg.
본 발명의 흑삼 및 그 추출물을 포함하는 조성물의 제제예를 설명하나, 본 발명은 이를 한정하고자 함이 아닌 단지 구체적으로 설명하고자 함이다.The preparation examples of the composition comprising the black ginseng and extracts of the present invention will be described, but the present invention is not intended to be limited thereto, but is intended to be described in detail.
제제예 1. 산제의 제조Formulation Example 1 Preparation of Powder
실시예 1의 흑삼 20 mgBlack ginseng 20 mg of Example 1
유당 100 mgLactose 100 mg
탈크 10 mgTalc 10 mg
상기의 성분들을 혼합하고 기밀포에 충진하여 산제를 제조한다.The above ingredients are mixed and filled in an airtight cloth to prepare a powder.
제제예Formulation example 2. 정제의 제조 2. Preparation of Tablets
실시예 2의 흑삼 조 사포닌 추출물 10 mgBlack ginseng crude saponin extract 10 mg of Example 2
옥수수전분 100 mgCorn starch 100 mg
유당 100 mgLactose 100 mg
스테아린산 마그네슘 2 mg2 mg magnesium stearate
상기의 성분들을 혼합한 후 통상의 정제의 제조방법에 따라서 타정하여 정제를 제조한다.After mixing the above components, tablets are prepared by tableting according to a conventional method for preparing tablets.
제제예Formulation example 3. 캅셀제의 제조 3. Manufacture of capsule
실시예 1의 흑삼 10 mgBlack ginseng of Example 1 10 mg
결정성 셀룰로오스 3 mg3 mg of crystalline cellulose
락토오스 14.8 mgLactose 14.8 mg
마그네슘 스테아레이트 0.2 mgMagnesium Stearate 0.2 mg
통상의 캡슐제 제조방법에 따라 상기의 성분을 혼합하고 젤라틴 캡슐에 충전하여 캡슐제를 제조한다.According to a conventional capsule preparation method, the above ingredients are mixed and filled into gelatin capsules to prepare capsules.
제제예Formulation example 4. 주사제의 제조 4. Preparation of injections
실시예 2의 흑삼 조 사포닌 추출물 10 mgBlack ginseng crude saponin extract 10 mg of Example 2
만니톨 180 mg180 mg mannitol
주사용 멸균 증류수 2974 mgSterile sterilized water for injection 2974 mg
Na2HPO4,12H2O 26 mgNa 2 HPO 4 , 12H 2 O 26 mg
통상의 주사제의 제조방법에 따라 1 앰플당(2㎖) 상기의 성분 함량으로 제조한다.According to the conventional method for preparing an injection, the amount of the above ingredient is prepared per ampoule (2 ml).
제제예Formulation example 5. 5. 액제의Liquid 제조 Produce
실시예 1의 흑삼 20 mgBlack ginseng 20 mg of Example 1
이성화당 10 g10 g of isomerized sugar
만니톨 5 g5 g of mannitol
정제수 적량Purified water
통상의 액제의 제조방법에 따라 정제수에 각각의 성분을 가하여 용해시키고 레몬향을 적량 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체를 정제수를 가하여 전체 100㎖로 조절한 후 갈색병에 충진하여 멸균시켜 액제를 제조한다.After dissolving each component in purified water according to the usual method of preparing a liquid solution, adding lemon flavor appropriately, mixing the above components, adding purified water, adjusting the whole to 100 ml by adding purified water, and then filling into a brown bottle. The solution is prepared by sterilization.
제제예Formulation example 6. 건강 식품의 제조 6. Manufacture of health food
실시예 2의 흑삼 조 사포닌 추출물 1000 ㎎1000 mg of black ginseng crude saponin extract of Example 2
비타민 혼합물 적량Vitamin mixture quantity
비타민 A 아세테이트 70 ㎍70 [mu] g of vitamin A acetate
비타민 E 1.0 ㎎Vitamin E 1.0 mg
비타민 B1 0.13 ㎎0.13 mg vitamin B1
비타민 B2 0.15 ㎎0.15 mg of vitamin B2
비타민 B6 0.5 ㎎0.5 mg vitamin B6
비타민 B12 0.2 ㎍0.2 [mu] g vitamin B12
비타민 C 10 ㎎10 mg vitamin C
비오틴 10 ㎍Biotin 10 μg
니코틴산아미드 1.7 ㎎Nicotinic acid amide 1.7 mg
엽산 50 ㎍50 ㎍ of folic acid
판토텐산 칼슘 0.5 ㎎Calcium pantothenate 0.5 mg
무기질 혼합물 적량Mineral mixture quantity
황산제1철 1.75 ㎎1.75 mg of ferrous sulfate
산화아연 0.82 ㎎0.82 mg of zinc oxide
탄산마그네슘 25.3 ㎎Magnesium carbonate 25.3 mg
제1인산칼륨 15 ㎎15 mg of potassium phosphate monobasic
제2인산칼슘 55 ㎎Secondary calcium phosphate 55 mg
구연산칼륨 90 ㎎Potassium citrate 90 mg
탄산칼슘 100 ㎎100 mg of calcium carbonate
염화마그네슘 24.8 ㎎Magnesium chloride 24.8 mg
상기의 비타민 및 미네랄 혼합물의 조성비는 비교적 건강식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강식품 조성물 제조에 사용할 수 있다.Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.
제제예Formulation example 7. 건강 음료의 제조 7. Manufacture of health drinks
실시예 1의 흑삼 1000 ㎎1000 mg of black ginseng of Example 1
구연산 1000 ㎎Citric acid 1000 mg
올리고당 100 g100 g of oligosaccharide
매실농축액 2 gPlum concentrate 2 g
타우린 1 gTaurine 1 g
정제수를 가하여 전체 900 ㎖Purified water was added to a total of 900 ml
통상의 건강음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간동안 85℃에서 교반 가열한 후, 만들어진 용액을 여과하여 멸균된 2ℓ 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 본 발명의 건강음료 조성물 제조에 사용한다. The above components were mixed according to a conventional health drink manufacturing method, and the mixture was heated at 85 DEG C for about 1 hour with stirring, and the solution thus prepared was filtered to obtain a sterilized 2-liter container, which was sealed and sterilized, ≪ / RTI >
상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.Although the composition ratio is a mixture of the components suitable for the preferred beverage as a preferred embodiment, the blending ratio may be arbitrarily varied according to the regional and national preferences such as the demand level, the demanding country, and the intended use.
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090048666A KR20100130020A (en) | 2009-06-02 | 2009-06-02 | A composition comprising novel black ginseng without tumor promoting agents such as benzopyran and the extract thereof obtained by novel process |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090048666A KR20100130020A (en) | 2009-06-02 | 2009-06-02 | A composition comprising novel black ginseng without tumor promoting agents such as benzopyran and the extract thereof obtained by novel process |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20100130020A true KR20100130020A (en) | 2010-12-10 |
Family
ID=43506477
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090048666A KR20100130020A (en) | 2009-06-02 | 2009-06-02 | A composition comprising novel black ginseng without tumor promoting agents such as benzopyran and the extract thereof obtained by novel process |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR20100130020A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102988229A (en) * | 2012-11-26 | 2013-03-27 | 薛美琪 | Treatment process of radix scrophulariae and preparation process of radix scrophulariae based cosmetic |
KR101706044B1 (en) * | 2016-01-13 | 2017-02-13 | 박석하 | Ginseng production method and apparatus using a high-temperature / high-pressure |
KR102295116B1 (en) * | 2020-10-23 | 2021-08-31 | 주식회사 한빛향료 | Manufacturing method of black ginseng to improve cognitive function and black ginseng manufactured by the method |
WO2022250210A1 (en) * | 2021-05-28 | 2022-12-01 | 주식회사 비티씨 | Method for preparing gynostemma pentaphyllum leaf tea, and method for preparing gynostemma pentaphyllum leaf tea extract using gynostemma pentaphyllum leaf tea prepared thereby |
-
2009
- 2009-06-02 KR KR1020090048666A patent/KR20100130020A/en not_active Application Discontinuation
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102988229A (en) * | 2012-11-26 | 2013-03-27 | 薛美琪 | Treatment process of radix scrophulariae and preparation process of radix scrophulariae based cosmetic |
KR101706044B1 (en) * | 2016-01-13 | 2017-02-13 | 박석하 | Ginseng production method and apparatus using a high-temperature / high-pressure |
KR102295116B1 (en) * | 2020-10-23 | 2021-08-31 | 주식회사 한빛향료 | Manufacturing method of black ginseng to improve cognitive function and black ginseng manufactured by the method |
WO2022086267A1 (en) * | 2020-10-23 | 2022-04-28 | 주식회사 한빛향료 | Method for preparation of black ginseng for improving cognitive function and black ginseng prepared by same method |
WO2022250210A1 (en) * | 2021-05-28 | 2022-12-01 | 주식회사 비티씨 | Method for preparing gynostemma pentaphyllum leaf tea, and method for preparing gynostemma pentaphyllum leaf tea extract using gynostemma pentaphyllum leaf tea prepared thereby |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101082181B1 (en) | A method for preparing novel black-red ginseng and the extract therefrom and the composition comprising the same | |
KR100754253B1 (en) | A novel process for preparing black ginseng and the composition comprising the same | |
KR100889950B1 (en) | A novel process for preparing red ginseng and the composition comprising the same | |
KR100860080B1 (en) | Pharmaceutical composition comprising the plant extract belonged to Veronica genus having anti-inflammatory, anti-allergic and-asthmatic activity | |
KR101906720B1 (en) | Composition comprising the combination extract of Lycium chinensis, Glycyrrhiza urlaensis FISCH, Foeniculum vulagare MILL, Glycine max MERR, and Pueraria thunbergiana BENTH for preventing and treating menopause-related disease and depression | |
KR101269208B1 (en) | Composition comprising sauchinone as an active ingredient for preventing or treating insulin resistance | |
KR20100130020A (en) | A composition comprising novel black ginseng without tumor promoting agents such as benzopyran and the extract thereof obtained by novel process | |
KR20080107924A (en) | Method for producing red-ginseng extract | |
KR100868249B1 (en) | A pharmaceutical composition and health care food comprising novel black ginseng leaf and the extract thereof showing anti-aging activity prepared by novel process | |
KR101210748B1 (en) | Composition comprising the extract of Acanthopanax sessiliflorus and green tea for treating or alleviating hangover syndrome | |
KR20140003705A (en) | Method for manufacturing red ginseng extract with enhanced function and the extact thereof | |
KR100844991B1 (en) | A composition comprising the extract of black ginseng leaf showing anti-cancer activity | |
KR100781571B1 (en) | Pharmaceutical composition comprising an extract of novel black ginseng | |
KR101423875B1 (en) | A composition comprising the complex extract for preventing or treating stroke and degenerative brain disease | |
KR101407188B1 (en) | A composition comprising an extract of fermented or non-fermented combined crude drugs for treating and preventing abnormal metabolic diseases | |
KR101082173B1 (en) | A method for preparation of flower bud of black ginseng and a composition comprising the extract thereof showing anti-aging activity | |
KR20110130857A (en) | Functional composition having anti-oxidative function, anti-allergic, improvement and prevention effect of atopic dermatitis, and method for manufacturing the same, and a healthful food having the same | |
KR101929664B1 (en) | Fermented-white ginseng extracts containing increased ginsenoside Rd, Rg3 and Rg5 and method thereof | |
KR100551464B1 (en) | Composition comprising an extract of Saururus chinensis BAILL. for preventing and treating diabetes mellitus | |
KR101082262B1 (en) | Composition comprising an extract of black ginseng showing anti-aging activity | |
KR20130000017A (en) | Composition for preventing and treating diabetics containing active ingredients separated from sorghum | |
KR100555653B1 (en) | Composition comprising an extract of processed Panax genus plant for preventing and treating anxiety | |
KR20080016291A (en) | A composition comprising novel black ginseng and the extract thereof for the prevention and treatment of diabetes mellitus prepared by novel process | |
KR20050043092A (en) | Composition comprising the extract of allium victorialis l. var. platyphyllum for treating or preventing diabetes mellitus | |
KR20130043767A (en) | A composition comprising the extract of processed panax genus plant for treating and preventing liver disease and hepato-protective activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |